Back to company

Amicus Therapeutics ApS: Financial statements 2022

CVR: 39359340

Amicus Therapeutics ApS (CVR 39359340) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK 1,575,511 and a net result of DKK 54,033 compared with DKK 19,351 the year before. That is an increase of 144.6% compared with the year before. Equity amounted to DKK 303,093. The solvency ratio was 49.1%. The company had 1 employee in the financial year.

Gross Profit
1,575,511 kr.
Profit/Loss
54,033 kr.
Equity
303,093 kr.
Total Assets
617,319 kr.
Employees
1

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2022-1.6 mio.54 t.303 t.1
2021-644 t.19 t.249 t.1
2020-490 t.22 t.230 t.1
2019-2 mio.84 t.208 t.2
2018-2 mio.74 t.124 t.2

Official annual report

View the official annual report directly on the page with a Pro subscription.

Keep an eye on Amicus Therapeutics ApS

Get notified instantly about new financial statements, ownership changes, management changes and status changes.

Set up monitoring

Events in 2022

Amicus Therapeutics ApS: The 2021 annual report is outJun 22, 2022

Amicus Therapeutics ApS has published its annual report for 2021. Gross profit came to DKK 644,168, and the net result was DKK 19,351.

About Amicus Therapeutics ApS

Amicus Therapeutics ApS is a Danish company of the type Anpartsselskab based in København V, founded in 2018. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The management consists of Richard Gideon Morris. The company is owned by Amicus Therapeutics UK Ltd.. The company has 2 employees. In 2025, the company reported a gross profit of DKK 1,441,140 and a net result of DKK 115,004 compared with DKK 16,475 the year before. Equity amounted to DKK 424,641.

Other financial years